Trial reportEuropean journal of medical research2022
Prediction of distant metastasis in esophageal cancer using a radiomics-clinical model.
Trial report in European journal of medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- AI in esophageal cancer: advances, barriers to clinical translation, and perspectives for digital health.Journal of translational medicine · 2026Review
- A rare case report on esophageal squamous cell carcinoma metastatic to the colon.Frontiers in oncology · 2026Article
- Predicting esophageal cancer response to neoadjuvant therapy with magnetic resonance imaging radiomics.World journal of gastrointestinal oncology · 2025Article
- The application of artificial intelligence in upper gastrointestinal cancers.Journal of the National Cancer Center · 2025Review
- Radiomics and prognostic nutritional index for predicting postoperative survival in esophageal carcinoma.European journal of medical research · 2025Article
- Delta-Radiomics Approach Using Contrast-Enhanced and Noncontrast-Enhanced Computed Tomography Images for Predicting Distant Metastasis in Patients With Borderline Resectable Pancreatic Carcinoma.Advances in radiation oncology · 2025Article
- Esophageal squamous cell carcinoma with colonic and rectal metastases: a rare case report.Frontiers in oncology · 2025Article
- IntegratingBMC cancer · 2024Article
- Review
- Gastro-Esophageal Cancer: Can Radiomic Parameters from BaselineDiagnostics (Basel, Switzerland) · 2024Article
- Clinical-radiomics nomogram for the risk prediction of esophageal fistula in patients with esophageal squamous cell carcinoma treated with intensity-modulated radiation therapy or volumetric-modulated arc therapy.Journal of thoracic disease · 2024Article
- Prediction of pCR based on clinical-radiomic model in patients with locally advanced ESCC treated with neoadjuvant immunotherapy plus chemoradiotherapy.Frontiers in oncology · 2024Article
- Rare Metastasis of Esophageal Adenocarcinoma to the Female Reproductive Tract.ACG case reports journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDistant metastasis, which occurs at a rate of 25% in patients with esophageal cancer (EC), has a poor prognosis, with previous studies reporting an overall survival of only 3-10 months. However, few studies have been conducted to predict distant metastasis in EC, owing to a dearth of reliable biomarkers. The purpose of this study was to develop and validate an accurate model for predicting distant metastasis in patients with EC.
methodsA total of 299 EC patients were enrolled and randomly assigned to a training cohort (n = 207) and a validation cohort (n = 92). Logistic univariate and multivariate regression analyses were used to identify clinical independent predictors and create a clinical nomogram. Radiomic features were extracted from contrast-enhanced computed tomography (CT) images taken prior to treatment, and least absolute shrinkage and selection operator (Lasso) regression was used to screen the associated features, which were then used to develop a radiomic signature. Based on the screened features, four machine learning algorithms were used to build radiomics models. The joint nomogram with radiomic signature and clinically independent risk factors was developed using the logical regression algorithm. All models were validated and compared by discrimination, calibration, reclassification, and clinical benefit.
resultsMultivariable analyses revealed that age, N stage, and degree of pathological differentiation were independent predictors of distant metastasis, and a clinical nomogram incorporating these factors was established. A radiomic signature was developed by a set of sixteen features chosen from 851 radiomic features. The joint nomogram incorporating clinical factors and radiomic signature performed better [AUC(95% CI) 0.827(0.742-0.912)] than the clinical nomogram [AUC(95% CI) 0.731(0.626-0.836)] and radiomics predictive models [AUC(95% CI) 0.754(0.652-0.855), LR algorithms]. Calibration and decision curve analyses revealed that the radiomics-clinical nomogram outperformed the other models. In comparison with the clinical nomogram, the joint nomogram's NRI was 0.114 (95% CI 0.075-0.345), and its IDI was 0.071 (95% CI 0.030-0.112), P = 0.001.
conclusionsWe developed and validated the first radiomics-clinical nomogram for distant metastasis in EC which may aid clinicians in identifying patients at high risk of distant metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.